Adverse effects associated with discontinuation of treatment were hyperglycemia ( 1 subject in the monotherapy trial ) and hypokinesia and tardive dyskinesia ( 1 subject each in adjunctive therapy trial ) .
The drugs are known to have significant risks and adverse reactions , including somnolence ; weight gain ; increases in blood lipids , triglycerides , and glucose ; hyperprolactinemia ; acute extrapyramidal symptoms ; and tardive dyskinesia .